Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Affimed N.V. (AFMD): OrbiMed Advisors Cuts Its Position

Page 1 of 12

A freshly-amended 13D filing with the US SEC showed that Sam Isaly’s OrbiMed Advisors has sold some of its shares of Affimed N.V. (NASDAQ:AFMD), hence its stake in the company currently consists of 3.38 million common shares (which include 326,650 shares that can be obtained upon the Carve-Out Agreement), representing 10.15% of the float. Previously, the fund’s stake stood at 3.78 million shares, according to its 13F filing for the end of June.

Affimed N.V. is a clinical-stage biopharmaceutical company that works on producing cancer immunotherapies. Since the beginning of the year, the company’s stock has lost 60.39%. For the second quarter of 2016, Affimed N.V. disclosed a loss per share of €0.24 ($0.27) missing the estimates of a loss per share of €0.20, and revenue of €2.1 million, topping the estimates of €1.9 million.

Samuel Isaly Orbimed Advisors

Among investors from our database, nine reported long positions in Affimed N.V. (NASDAQ:AFMD) at the end of June, up by one from the previous quarter. Some of the bullish investors include Bain Capital’s Brookside Capital with a position valued at $5.20 million, James A. Silverman’s Opaleye Management which held a position worth around $1.48 million, Louis Bacon’s Moore Capital Management, and Julian and Felix Baker’s Baker Bros. Advisors.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
OrbiMed Advisors 0 3,375,000 0 3,375,000 3,375,000 10.15%
OrbiMed Capital GP III 0 3,343,965 0 3,343,965 3,343,965 10.05%
Samuel D. Isaly 0 3,375,000 0 3,375,000 3,375,000 10.15%

Samuel Isaly
Samuel Isaly
OrbiMed Advisors

Page 1 of 12 – SEC Filing

Washington, D.C. 20549
Under the Securities Exchange Act of 1934
(Amendment No. 6)*


(Name of Issuer)


(Title of Class of Securities)


(CUSIP Number)
OrbiMed Advisors LLC
OrbiMed Capital GP III LLC
Samuel D. Isaly
601 Lexington Avenue, 54th Floor
New York, NY 10022

Telephone:  (212) 739-6400

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

September 22, 2016

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of § 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box £.
Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See § 240.13d-7(b) for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Follow Affimed N.v.
Trade () Now!
Page 1 of 12

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!